Acquired Amegakaryocytic Thrombocytopenia Progressingto Aplastic Anaemia

  • Syed Ather Hussain Department of Internal Medicine, Rochester General Hospital, Rochester, NY, USA
  • Huda Fatima Department of Internal Medicine, Mercy Health St. Vincent Medical Center, Toledo, OH, USA
  • Hafsa Faisal Department of Internal Medicine, Rochester General Hospital, Rochester, NY, USA
  • Meenakshi Bansal Department of Pathology, Rochester General Hospital, Rochester, NY, USA

Keywords

Acquired amegakaryocytic thrombocytopenia, aplastic anaemia, haematopoietic stem cell transplant

Abstract

Acquired amegakaryocytic thrombocytopenia (AAMT) is a rare disorder of the bone marrow characterized by a lack of megakaryocytes and preservation of other cell lines. It can occur due to an intrinsic stem cell defect or secondary to viral infections, autoimmune disorders, lymphoproliferative disorders or environmental toxins. With time, it can progress to aplastic anaemia (AA) and can have a poor prognosis. No standard guidelines exist for the treatment of AAMT progressing to AA. Herein, we report a rare case of AAMT leading to AA and review the handful of cases previously published in the literature.

VIEW THE ENTIRE ARTICLE

References

  • Roy AM, Konda M, Sidarous GK, Atwal D, Schichman SA, Kunthur A. Acquired amegakaryocytic thrombocytopenia misdiagnosed as immune thrombocytopenia: a case report. Perm J 2020;24:1–3. doi:10.7812/TPP/19.203.
  • Levy I, Laor R, Jiries N, Bejar J, Polliack A, Tadmor T. Amegakaryocytic thrombocytopenia and subsequent aplastic anemia associated with apparent Epstein-Barr virus infection. Acta Haematol 2018;139(1):7–11. doi:10.1159/000484595.
  • Hoffman R. Acquired pure amegakaryocytic thrombocytopenic purpura. Semin Hematol 1991;28(4):303–312.
  • Novotný JP, Köhler B, Max R, Egerer G. Acquired amegakaryocytic thrombocytopenic purpura progressing into aplastic anemia. Prague Med Rep 2018;118(4):147–155.
  • Simkins A, Maiti A, Short NJ, Jain N, Popat U, Patel KP, et al. Acquired amegakaryocytic thrombocytopenia and red cell aplasia in a patient with thymoma progressing to aplastic anemia successfully treated with allogenic stem cell transplantation. Hematol Oncol Stem Cell Ther 2019;12(2):115–118.
  • Stoll DB, Stuart B, Pasquale D, Murphy S. Thrombocytopenia with decreased megakaryocytes: evaluation and prognosis. Ann Intern Med 1981;94(2):170–175. doi:10.7326/0003-4819-94-2-170.
  • Hoffman R, Bruno E, Elwell J, Mazur E, Gewirtz AM, Dekker P, et al. Acquired amegakaryocytic thrombocytopenic purpura: a syndrome of diverse etiologies. Blood 1982;60(5):1173–1178.
  • Slater LM, Katz J, Walter B, Armentrout SA. Aplastic anemia occurring as amegakaryocytic thrombocytopenia with and without an inhibitor of granulopoiesis. Am J Hematol 1985;18(3):251–254. doi:10.1002/ajh.2830180305.
  • King JA, Elkhalifa MY, Latour LF. Rapid progression of acquired amegakaryocytic thrombocytopenia to aplastic anemia. South Med J 1997;90(1):91–94. doi:10.1097/00007611-199701000-00024.
  • Tu X, Xue A, Wu S, Jin M, Zhao P, Zhang H. Case report: successful avatrombopag treatment for two cases of anti-PD-1 antibody-induced acquired amegakaryocytic thrombocytopenia. Front Pharmacol 2022;12:795884. doi:10.3389/fphar.2021.795884.
  • Published: 2022-09-05

    Issue: 2022: LATEST ONLINE (view)

    Section: Articles

    How to cite:
    1.
    Hussain SA, Fatima H, Faisal H, Bansal M. Acquired Amegakaryocytic Thrombocytopenia Progressingto Aplastic Anaemia. EJCRIM 2022;doi:10.12890/2022_003479.